MedCity News October 6, 2023
Precede Biosciences’ liquid biopsy platform yields insight into the genes and pathways in diseased tissue. Based on Dana-Farber Cancer Institute research, the startup aims to support biopharma drug R&D as it also develops the technology for clinical care applications.
Cancer care is becoming more targeted with the development of therapies that address specific genetic signatures. Before such drugs are used, a test identifies whether a patient’s cancer matches an available therapy. A blood test called a liquid biopsy can provide that answer—but not for all genetic signatures. For example, a growing number of drugs target HER2, a cancer-driving protein found in many breast cancers. Testing for this protein requires a more invasive tissue biopsy.
Precede Biosciences aims to bring liquid...
Today's Sponsors
Today's Sponsor